BENSALEM, Pa.--(BUSINESS WIRE)--
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of all purchasers of Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (AEGR) securities between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”). If you purchased Aegerion shares during the Class Period, you may move the Court no later than March 17, 2014, to serve as lead plaintiff, if you meet certain legal requirements.
Aegerion markets its cholesterol drug Juxtapid in the United States. Juxtapid is a treatment for patients with homozygous familial hypercholesterolemia (HoFH) – a rare genetic disease that impairs the function of the receptor responsible for removing LDL-C or “bad” cholesterol from the blood. The Complaint, filed in the United States District Court for the District of Massachusetts, alleges that Aegerion’s marketing practices during the Class Period were in violation of the Food, Drug, and Cosmetic Act (FDCA), and that defendants made false and misleading statements or failed to disclose to Aegerion investors that the Company marketed its drugs in violation of the FDCA. On January 10, 2014, Aegerion received a subpoena from the U.S. Department of Justice requesting documents regarding its marketing and sale of Juxtapid. As a result of this news, Aegerion shares declined $7.98 per share, or nearly 11%, to close at $65.77 per share on January 10, 2013.
If you wish to learn more about this action or if you purchased Aegerion stock prior to March 15, 2012, and still hold those shares, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
- Company Legal & Law Matters
- Health Care Industry